Paschalis Karakasis
Overview
Explore the profile of Paschalis Karakasis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
147
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Karakasis P, Theofilis P, Patoulias D, Vlachakis P, Antoniadis A, Fragakis N
Int J Mol Sci
. 2025 Mar;
26(5).
PMID: 40076813
The global rise in diabetes prevalence has significantly contributed to the increasing burden of atherosclerotic cardiovascular disease (ASCVD), a leading cause of morbidity and mortality in this population. Diabetes accelerates...
2.
Karakasis P, Lefkou E, Pamporis K, Farmakis D, Patoulias D, Antoniadis A, et al.
Eur J Heart Fail
. 2025 Mar;
PMID: 40064512
Aims: Clonal haematopoiesis (CH) is recognized as a significant risk factor for various non-haematologic conditions, including cardiovascular diseases. However, recent studies examining its relationship with heart failure (HF) have reported...
3.
Karakasis P, Fragakis N, Ruza I, Stachteas P, Patoulias D
Future Cardiol
. 2025 Mar;
:1-4.
PMID: 40055143
No abstract available.
4.
Pamporis K, Karakasis P, Sagris M, Theofilis P, Milaras N, Pantelidaki A, et al.
Eur J Prev Cardiol
. 2025 Mar;
PMID: 40053837
Aim: Asymptomatic atrial fibrillation (AF) is frequent and associated with disease progression. This meta-analysis aimed to estimate the prevalence of asymptomatic AF and identify risk factors associated with asymptomatic status....
5.
Theofilis P, Papanikolaou A, Karakasis P, Dimitriadis K, Vlachakis P, Oikonomou E, et al.
Expert Rev Cardiovasc Ther
. 2025 Mar;
:1-7.
PMID: 40040242
Introduction: Coronary atherosclerosis, marked by lipid deposition and inflammation, drives cardiovascular morbidity. Traditional treatments focus on lipid reduction, yet newer therapies target plaque composition, aiming to enhance stability and prevent...
6.
Karakasis P, Lefkou E, Patoulias D, Fragakis N
Acta Cardiol
. 2025 Feb;
:1-2.
PMID: 40007154
No abstract available.
7.
Klisic A, Gluscevic S, Karakasis P, Kotur-Stevuljevic J, Ninic A
J Med Biochem
. 2025 Feb;
44(1):85-92.
PMID: 39991168
Background: The clinical utility of galectin-3 and fibroblast growth factor 23 (FGF-23) needs to be further explored since previous studies show divergent results in relation to type 2 diabetes (T2D)...
8.
Karakasis P, Patoulias D, Fragakis N, Gomez-Huelgas R
Eur J Intern Med
. 2025 Feb;
PMID: 39986942
No abstract available.
9.
Pamporis K, Karakasis P, Tsiachris D
J Cardiothorac Vasc Anesth
. 2025 Feb;
PMID: 39956686
No abstract available.
10.
Sagris M, Ktenopoulos N, Pamporis K, Gerogianni M, Karakasis P, Theofilis P, et al.
Curr Vasc Pharmacol
. 2025 Feb;
PMID: 39950453
Introduction: Current guidelines and consensus statements advise caution in using direct oral anticoagulants (DOACs) for morbidly obese patients with body mass index (BMI) >40 kg/m2, indicating warfarin as the most...